Patents by Inventor Brian R. Boettcher
Brian R. Boettcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240261372Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: February 7, 2024Publication date: August 8, 2024Inventors: BRIAN R. BOETTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
-
Patent number: 11944664Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: August 24, 2021Date of Patent: April 2, 2024Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Publication number: 20210386824Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 24, 2021Publication date: December 16, 2021Applicant: Novartis AGInventors: BRIAN R. BOETTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
-
Patent number: 11129874Abstract: The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.Type: GrantFiled: August 30, 2018Date of Patent: September 28, 2021Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 10669323Abstract: The present invention relates to the identification of dual function fusion proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating metabolic, cardiovascular, and endocrine conditions related to glucose and/or lipid homeostasis.Type: GrantFiled: August 26, 2016Date of Patent: June 2, 2020Assignee: NOVARTIS AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Susan E. Cellitti, Douglas S. Daniels, Norio Hamamatsu, Bernhard Hubert Geierstanger, Stuart Licht, Andreas Loew, Stephen Craig Weldon
-
Publication number: 20180369332Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 30, 2018Publication date: December 27, 2018Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 10076554Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: January 4, 2016Date of Patent: September 18, 2018Assignee: Novartis AGInventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Publication number: 20170166621Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 26, 2016Publication date: June 15, 2017Applicant: NOVARTIS AGInventors: Brian R. BOETTCHER, Shari Lynn CAPLAN, Susan E. CELLITTI, Douglas S. DANIELS, Norio HAMAMATSU, Bernhard Hubert GEIERSTANGER, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
-
Patent number: 9458214Abstract: The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.Type: GrantFiled: September 25, 2012Date of Patent: October 4, 2016Assignee: NOVARTIS AGInventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon, Susan E. Cellitti, Bernhard Hubert Geierstranger, Andreas Loew
-
Publication number: 20160051628Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: April 2, 2015Publication date: February 25, 2016Applicants: IRM LLC, NOVARTIS AGInventors: Brian R. BOETTCHER, Andreas LOEW, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Stephen Craig WELDON
-
Patent number: 9266935Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: February 24, 2015Date of Patent: February 23, 2016Assignee: Novartis AGInventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Publication number: 20150166622Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: February 24, 2015Publication date: June 18, 2015Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Patent number: 9023791Abstract: The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.Type: GrantFiled: November 15, 2011Date of Patent: May 5, 2015Assignees: Novartis AG, IRM LLCInventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Bernhard H. Geierstanger, Norio Hamamatsu, Stuart Licht, Andreas Loew, Stephen Craig Weldon
-
Patent number: 9006400Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: GrantFiled: September 25, 2012Date of Patent: April 14, 2015Assignee: Novartis AGInventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Publication number: 20130079500Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: September 25, 2012Publication date: March 28, 2013Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
-
Publication number: 20120129766Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.Type: ApplicationFiled: November 15, 2011Publication date: May 24, 2012Applicants: IRM LLC, NOVARTIS AGInventors: Brian R. BOETTCHER, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
-
Patent number: 6608038Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.Type: GrantFiled: March 14, 2001Date of Patent: August 19, 2003Assignee: Novartis AGInventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai
-
Publication number: 20020065239Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.Type: ApplicationFiled: March 14, 2001Publication date: May 30, 2002Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai